OpenLB
Open Library of Bioscience
Advanced Search
Echocardiography (Mount Kisco, N.Y.)
03, 2022;39 (3): 483-489.

Relationship of warfarin versus DOACs with thrombogenic milieu in the left atrium among patients with nonvalvular atrial fibrillation.

Takahide Ito, Kanako Akamatsu, Hitomi Hasegawa, Yuka Sakatani, Masatoshi Miyamura, Masaaki Hoshiga
Author Information
  1. Takahide Ito: Department of Cardiology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
  2. Kanako Akamatsu: Department of Cardiology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
  3. Hitomi Hasegawa: Department of Cardiology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
  4. Yuka Sakatani: Department of Cardiology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
  5. Masatoshi Miyamura: Department of Cardiology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
  6. Masaaki Hoshiga: Department of Cardiology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
PMID: 35137446 DOI: 10.1111/echo.15319

Abstract

BACKGROUND: Thrombogenic milieu (TM) within the left atrium plays a pivotal role in the pathogenesis of thromboembolic events, for which anticoagulation treatment is indicated typically on the mandatory basis. Little is known, however, about which regimen of anticoagulation, warfarin or direct oral anticoagulants (DOACs), is more likely associated with TM. We evaluated relative relationship of the two treatment options with concurrently-observed TM in patients with nonvalvular atrial fibrillation (AF) who underwent transesophageal echocardiography.
METHODS: TM was defined as the presence of either left atrial spontaneous echo contrast (SEC) or thrombus, or both. To determine which regimen was more likely related to TM, we firstly compared the prevalence of TM in 208 patients taking warfarin (Warfarin group) versus 486 patients taking DOACs (DOAC group); and secondly, did the same analysis after propensity score matching.
RESULTS: Warfarin group was more likely associated with TM compared with DOAC group (46% vs 29%, p < 0.001). Similar findings were observed for dense SEC (18% vs 7%, p < 0.001) and thrombus (4% vs 1%, p = 0.057). The propensity score matching (198 patients for each group), where several baseline parameters were matched including age, gender, chronicity of AF, estimated glomerular filtration rate and B-type natriuretic peptide as well as the left ventricular ejection fraction, resulted in similar findings to the original groups (TM, 47% vs 32%, p = 0.002; dense SEC, 18% vs 7%, p = 0.001; thrombus, 4% vs 1%, p = 0.047).
CONCLUSIONS: This study may strengthen the data on randomized trials that DOACs are superior to warfarin in preventing thromboembolic events in nonvalvular AF patients. Further studies are required to elucidate the details behind this difference.

Keywords

anticoagulation atrial fibrillation atrial thrombus spontaneous echo contrast transesophageal echocardiography

References

  1. Archer SL, James KE, Kvernen LR, et al. Role of transesophageal echocardiography in the detection of left atrial thrombus in patients with chronic nonrheumatic atrial fibrillation. Am Heart J. 1995;130:287-295.
  2. Leung DY, Black IW, Cranney GB, et al. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol. 1994;24:755-762.
  3. Illien S, Maroto-Järvinen S, von der Recke G, et al. Atrial fibrillation: relation between clinical risk factors and transoesophageal echocardiographic risk factors for thromboembolism. Heart. 2003;89:165-168.
  4. Fatkin D, Herbert E, Feneley MP. Hematologic correlates of spontaneous echo contrast in patients with atrial fibrillation and implications for thromboembolic risk. Am J Cardiol. 1994;73:672-676.
  5. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
  6. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
  7. Sommerauer C, Schlender L, Krause M, et al. Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults: a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing. BMC Geriatr. 2017;17(1):223.
  8. Kim YG, Choi JI, Kim MN, et al. Non-vitamin K antagonist oral anticoagulants versus warfarin for the prevention of spontaneous echo-contrast and thrombus in patients with atrial fibrillation or flutter undergoing cardioversion: a trans-esophageal echocardiography study. PLoS One. 2018;13:e0191648.
  9. Watanabe T, Shinoda Y, Ikeoka K, et al. Dabigatran exhibits low intensity of left atrial spontaneous echo contrast in patients with nonvalvular atrial fibrillation as compared with warfarin. Heart Vessels. 2017;32:326-332.
  10. Iwakura K, Okamura A, Koyama Y, et al. Effect of elevated left ventricular diastolic filling pressure on the frequency of left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Am J Cardiol. 2011;107:417-422.
  11. Magnocavallo M, Bellasi A, Mariani MV, et al. Thromboembolic and bleeding risk in atrial fibrillation patients with chronic kidney disease: role of anticoagulation therapy. J Clin Med. 2020;10:83.
  12. Kizawa S, Ito T, Akamatsu K, et al. Kidney disease as a possible predictor of left atrial thrombogenic milieu among patients with nonvalvular atrial fibrillation. Am J Cardiol. 2018;122:2062-2067.
  13. Han D, Chu Y, Wu Y, et al. Determinants of left atrial thrombus or spontaneous echo contrast in nonvalvular atrial fibrillation. Thromb Res. 2020;195:233-237.
  14. Kim DH, Pieper CF, Ahmed A, et al. Use and interpretation of propensity scores in aging research: a guide for clinical researchers. J Am Geriatr Soc. 2016;64:2065-2073.
  15. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imag. 2015;16:233-270.
  16. Daniel WG, Nellessen U, Schröder E, et al. Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk. J Am Coll Cardiol. 1988;11:1204-1211.
  17. Beppu S, Nimura Y, Sakakibara H, et al. Smoke-like echo in the left atrial cavity in mitral valve disease: its features and significance. J Am Coll Cardiol. 1985;6:744-749.
  18. Fu Y, Li K, Gao Y, Wang L, et al. A novel risk score for predicting left atrial and left atrial appendage thrombogenic milieu in patients with non-valvular atrial fibrillation. Thromb Res. 2020;192:161-166.
  19. Fu Y, Li K, Yang X. ABO blood groups: a risk factor for left atrial and left atrial appendage thrombogenic milieu in patients with non-valvular atrial fibrillation. Thromb Res. 2017;156:45-50.
  20. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2):S1-266.
  21. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The stroke prevention in atrial fibrillation investigators committee on echocardiography. Ann Intern Med 1998;128:639-647.
  22. Frenkel D, D'Amato SA, Al-Kazaz M, et al. Prevalence of left atrial thrombus detection by transesophageal echocardiography: a comparison of continuous non-vitamin K antagonist oral anticoagulant versus warfarin therapy in patients undergoing catheter ablation for atrial fibrillation. JACC Clin Electrophysiol. 2016;2:295-303.
  23. Kawabata M, Goya M, Sasaki T, et al. Left atrial appendage thrombi formation in Japanese non-valvular atrial fibrillation patients during anticoagulation therapy: warfarin vs. direct oral anticoagulants. Circ J. 2017;81:645-651.
  24. Lip GY, Hammerstingl C, Marin F, et al. Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016;178:126-134.
  25. Fleddermann A, Eckert R, Muskala P, et al. Efficacy of direct acting oral anticoagulant drugs in treatment of left atrial appendage thrombus in patients with atrial fibrillation. Am J Cardiol. 2019;123:57-62.
  26. Nagamoto Y, Shiomi T, Matsuura T, et al. Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran. Heart Vessels. 2014;29:560-562.
  27. Kao PH, Chou PY, Hsu PC, et al. Resolution of left ventricular thrombus by edoxaban after failed treatment with warfarin overdose: a case report. Medicine. 2019;98:e14065.
  28. Ito T, Suwa M, Nakamura T, et al. Influence of warfarin therapy on left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. Am J Cardiol. 1999;84:857-859.
  29. Merino A, Hauptman P, Badimon L, et al. Echocardiographic “smoke” is produced by an interaction of erythrocytes and plasma proteins modulated by shear forces. J Am Coll Cardiol. 1992;20:1661-1668.
  30. Black IW, Chesterman CN, Hopkins AP, et al. Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol. 1993;21:451-457.
  31. Huntington JA. Molecular recognition mechanisms of thrombin. J Thromb Haemost. 2005;3:1861-1872.
  32. Black IW, Hopkins AP, Lee LC, et al. Left atrial spontaneous echo contrast: a clinical and echocardiographic analysis. J Am Coll Cardiol. 1991;18:398-404.
  33. Rader VJ, Khumri TM, Idupulapati M, et al. Clinical predictors of left atrial thrombus and spontaneous echocardiographic contrast in patients with atrial fibrillation. J Am Soc Echocardiogr. 2007;20:1181-1185.
  34. Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: the J-ROCKET AF study. Circ J. 2012;76:2104-2111.
  35. Bernhardt P, Schmidt H, Hammerstingl C, et al. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk: a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Coll Cardiol. 2005;45:1807-1812.

MeSH Term

Administration, Oral
Anticoagulants
Atrial Fibrillation
Heart Atria
Humans
Stroke
Stroke Volume
Ventricular Function, Left
Warfarin

Chemicals

Anticoagulants
Warfarin
Journal Article

Word Cloud

Similar Articles

Cited By